NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and ...
Assembly Mag6h
Hyundai and Kia Invent Exoskeleton to Reduce Shoulder Strain
SEOUL—Hyundai Motor Co. and Kia Corp. have invented a “wearable robot” that promises to increase worker efficiency and reduce ...
Men's Fitness on MSN9h
PT Alex Crockford’s favorite 30-minute upper-body workout
Work every muscle from the waist up with this 30-minute workout from personal trainer and bulk ambassador Alex Crockford The ...